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Abstract
Human recombinant arginase I cobalt coupled to polyethylene glycol 5000 (HuArg I [Co]-PEG5000) achieved potent
in vitro depletion of arginine from tissue culture medium and cytotoxicity to many cancer cell lines. The recombi-
nant enzyme also produced tumor growth inhibition of hepatocellular carcinoma and pancreatic carcinoma xeno-
grafts. Although these results were promising, the therapeutic index was narrow. Toxicities were seen in normal
cells in tissue culture. In vivo normal tissue injury occurred at doses twice the effective dose. The current study
was conducted to define, in greater detail, the maximum tolerated dose (MTD), pharmacodynamics, and dose-
limiting toxicities (DLTs) of twice-weekly intraperitoneal HuArg I [Co]-PEG5000 in Balb/c mice. Animal weight
and survival were monitored, serum arginine levels measured, and complete blood cell counts, chemistries, necrop-
sies, and histologies were performed. In addition, methods to ameliorate the HuArg I [Co]-PEG5000 adverse effects
were tested. Supplemental L-citrulline was given concurrently with the arginase drug. The HuArg I [Co]-PEG5000MTD
in mice was 5 mg/kg twice weekly, and DLTs included weight loss and marrow necrosis. No other organ damage
or changes in blood cell counts or chemistries were observed. Arginase reduced serum arginine levels from
60 μM to 4 to 6 μM. Supplemental L-citrulline given per os or daily subcutaneously reduced and delayed toxicities,
and L-citrulline given twice daily subcutaneously completely prevented animal toxicities. On the basis of these results,
we hypothesize that HuArg I [Co]-PEG5000, particularly with supplemental L-citrulline, may be an attractive therapeutic
agent for argininosuccinate synthetase–deficient tumors.
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Introduction
Metastatic carcinoma patients receive limited benefit from chemo-
therapy, and therapeutic agents that target cancer cell–dependent
molecular pathways have been developed. Nonessential amino acid
auxotrophy has been observed in a number of different malignancies,
and tumor cell dependence on arginine has been correlated with tumor
cell deficiency of the urea cycle enzymes—ornithine transcarbamylase
(OTC) and/or argininosuccinate synthetase (ASS) [1]. Two different
arginine-depleting proteins—arginine deiminase and arginase—have
been produced and tested clinically in patients withmetastatic melanoma
and/or hepatocellular carcinoma [2,3]. Although remissions were ob-
served in some cases, immunogenicity of the arginine deiminase and
low potency and stability of the arginase inhibited efficacy. Recently,
we prepared a pegylated recombinant human arginase I containing
two Co2+ atoms instead of the Mn2+ atoms [4]. The molecule had
improved catalytic activity, stability, and reduced immunogenicity
relative to the other arginine-depleting molecules. We then examined
the sensitivity of human normal and malignant cells [5]. Human
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recombinant arginase I cobalt coupled to polyethylene glycol 5000
(HuArg I [Co]-PEG5000) was cytotoxic to all normal and tumor cell
lines. This finding correlated with the absence of OTC from most nor-
mal and malignant cells. In the presence of excess L-citrulline, selective
cytotoxicity was observed for ASS-deficient tumors and a few normal
tissues. The results were consistent with the rescue of arginine synthesis
in normal tissues with the L-citrulline (Figure 1). A pilot animal study
evaluated the safety and efficacy of HuArg I [Co]-PEG5000 alone [6].
Single doses or weekly doses of enzyme yielded a maximum tolerated
dose (MTD) of 8 mg/kg intraperitoneal (i.p.) and dose-limiting toxici-
ties (DLTs) of weight loss and marrow damage. Tumor growth inhibi-
tion of 46% and 58% was observed for hepatocellular carcinoma and
pancreatic carcinoma xenografts, respectively. On the basis of our tissue
culture results, in this study, we sought to test the in vivo effects of
supplemental L-citrulline on HuArg I [Co]-PEG5000 toxicity. We also
assessed different L-citrulline doses and delivery methods and a twice-
weekly HuArg I [Co]-PEG5000 dose regimen, performed pharmacody-
namic studies of serum arginine concentrations, and did complete blood
cell counts, blood chemistries, necropsies, and histopathology on animals.
Materials and Methods
Reagents
HuArg I [Co]-PEG5000 was produced from purified HuArg I
expressed in Escherichia coli [6]. Briefly, enzyme in 100 mM sodium
phosphate pH 8.3 was reacted with a 40-fold excess of methoxy PEG
succinimidyl carboxymethyl ester 5000 MW (JemKem Technology,
Allen, TX) for 1 hour at 25°C. The mixture was then incubated with
10mM cobalt chloride hexahydrate (MP Biomedicals, Solon, OH) and
heated to 50°C for 10 minutes. HuArg I [Co]-PEG5000 was then
centrifuged, dialyzed into phosphate-buffered saline (PBS) with 10%
glycerol, sterile filtered, aliquoted, and stored at −80°C until used.
L-Citrulline was purchased from Sigma-Aldrich (St Louis, MO).
Animals
Six- to eight-week-old female Balb/c mice were purchased from
Jackson Laboratories (Bar Harbor, ME) and housed in ventilated
cages equipped with municipal water and standard rodent chow con-
taining 1.4% arginine (Purina LabDiet 5001). Animals were weighed
daily and examined twice daily for activity, eating, posture, and coat
condition. Mice received 1 ml of Dulbecco PBS subcutaneously daily
for weight loss exceeding 10%. In addition, supplemental nutrition
with DietGel, water gels, and dry cereal mix was provided. Moribund
animals or animals losing more than 25% body weight were killed by
CO2 asphyxiation, and cardiac puncture was performed to collect
blood. Full necropsies were done, and tissue histopathology was per-
formed with formalin-fixed, paraffin-embedded 6-μm hematoxylin/
eosin–stained sections of brain, lung, liver, heart, stomach, intestine,
colon, kidney, pancreas, bladder, skin, uterus, muscle, and bone mar-
row. Blood cell counts and chemistries were performed on an Abaxis
(Union City, CA) VetScan HM2 and VS, respectively.
HuArg I [Co]-PEG5000 Dose Studies
Cohorts of 10 to 20 mice received 1, 5, or 10 mg/kg HuArg I
[Co]-PEG5000 twice weekly for up to 4 weeks. Animals were mon-
itored for weight, overall condition, and survival. One hundred micro-
liters of blood was collected from facial vein of surviving animals on
days 7 and 28. Blood was mixed with equal volume 0.1M citrate buffer
pH 6.6, plasma was separated, and the solution was stored at −80°C.
Moribund animals and animals completing the study were assayed for
tissue histology and blood cell counts and chemistries as described.
L-Citrulline Supplementation Experiments
Cohorts of 20 animals received 10 mg/kg HuArg I [Co]-
PEG5000 i.p. twice weekly for 2 weeks with daily 1 ml of PBS
subcutaneously daily, with 1 ml of 100 mg/ml L-citrulline in PBS sub-
cutaneously daily, with 1 ml of 100 mg/ml L-citrulline in PBS
subcutaneously twice daily, or with L-citrulline in drinking water
Figure 1. Urea cycle pathway and arginine deiminase. ADI indicates arginine deiminase; ASL, argininosuccinate lyase; ARGase, arginase.
Tumors often lack ASS. Normal tissues frequently lack OTC. ADI is from microbial source. ARGase are intracellular enzymes of liver and
other organs.
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at 100 mg/ml. Animals were again monitored for weight, overall con-
dition, and survival.
Serum Arginine Concentrations
Freshly obtained or thawed plasma was mixed with perchloric
acid, neutralized with potassium carbonate, and centrifuged. Super-
natants were reacted with 30 mM o-phthalaldehyde (OPA), 50 mM
2-mercaptoethanol, 40 mM sodium borate, and 3.1% Brij-35 pH 9.5.
Samples and standards (Sigma-Aldrich) were run immediately on a
Supelcosil LC-18 (Sigma-Aldrich) high-performance liquid chromatog-
raphy (Shimadzu, Tokyo, Japan) with a gradient of 86% 0.1M sodium
acetate pH 7.2/14% methanol to 100% methanol as described by Wu
and Meininger [7]. Fluorescence is monitored at excitation and emis-
sion wavelengths of 340 and 455 nm, respectively. Area under the curve
was calculated and correlated with standards. The assay range was 4 to
100 μM arginine.
Statistics
Mean and SDs were used to summarize continuous variables.
Different dose groups were compared with control groups using a
Mann-Whitney test. Survival analyses were performed using Kaplan-
Meier survival curves, and median survival time was calculated. The
comparison of two or more groups was performed using the log-rank
test, considering the threshold value P≤ .05. Analyses were performed
in R 2.12.1 (R development, 2010).
Results
HuArg I [Co]-PEG5000 Mouse Toxicity
The MTD of HuArg I [Co]-PEG5000 administered i.p. twice
weekly to Balb/c mice was 5 mg/kg. As shown in Figure 2, control
and 1 mg/kg protein yielded 100% survival, 5 mg/kg produced 90%
survival, and 10 mg/kg led to 10% survival. Lethality occurred within
10 days of treatment initiation. The difference in survival between the
control, 1 and 5 mg/kg were not significant; the differences in survival
between control and 10 mg/kg and between the 5- and 10-mg/kg dose
levels were significant (P < .001) as determine by log-rank tests. The
DLT was extreme weight loss (Figure 3) and marrow necrosis (Figure 4).
No abnormalities in blood cell counts, chemistries, or other organ histo-
pathology were seen.
Plasma Arginine Concentrations
Control mouse plasma arginine levels averaged 61 ± 19 and 44 ±
15 μM on days 7 and 28 of the experiment, respectively (Table 1).
HuArg I [Co]-PEG5000 1 mg/kg treated animals yielded arginine
concentrations of 32 ± 30 and 54 ± 22 μM on days 7 and 28, re-
spectively. In contrast, HuArg I [Co]-PEG5000 5 mg/kg gave 7 ± 2
and 18 ± 20 μM on days 7 and 28, respectively; HuArg I [Co]-
PEG5000 10 mg/kg produced 6 ± 2 μM arginine levels on day 7.
There were no surviving mice at this dose on day 28. Both the 5- and
10-mg/kg-treated plasma arginine levels were significantly lower than
the control and 1-mg/kg-dose-level plasma levels on day 7 (P < .001)
and day 28 for the surviving 5-mg/kg mice (P < .01).
L-Citrulline Protection
Because all deaths from HuArg I [Co]-PEG5000 occurred within
10 days, we designed the protection study to last 2 weeks. L-Citrulline
Figure 2. Kaplan-Meier plot of mice survival at different dose levels
of HuArg I [Co]-PEG5000 therapy. Animals were dosed i.p. twice
weekly for 4 weeks.
Figure 3. Percent mean weight loss from baseline for HuArg I [Co]-PEG5000–treated mice at different times of postinitiation therapy.
Error bars represent SEM. Arrows indicate days of arginase injections. *P < .001, #P < .005, ±P < .05 compared with control.
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was given either as 100-mg (5 g/kg) bolus subcutaneously injection
daily or twice daily or at 100 mg/ml in drinking water to HuArg I
[Co]-PEG5000 10-mg/kg-treated animals for 2 weeks. L-Citrulline
supplementation ameliorated the HuArg I [Co]-PEG5000 toxicities
in all treated cohorts. Animals treated with either daily or twice-daily
subcutaneous L-citrulline survived the entire 2 weeks (Figure 5). Some
orally supplemented animals stopped taking fluids and thus lost
L-citrulline protection and were killed because of extreme weight loss.
The difference in survival was highly significant for all citrulline inter-
ventions compared with control or animals treated with PBS sub-
cutaneously twice daily (P < .01). Weight loss was reduced from an
average of more than 30% to 0% or 17% (Figure 6). Animals treated
with L-citrulline supplementation showed improved bone marrow
histology after being allowed to recover for 2 weeks (Figure 3).
Discussion
Arginine depletion therapy for arginine auxotrophic malignancies is
an active area of clinical investigation. We are producing HuArg I
[Co]-PEG5000 under Good Manufacturing Practice guidelines for
clinical studies. Thus, accurate information on likely MTD, DLTs,
and pharmacodynamics are of great importance for clinical protocol
design and identification of interventions to reduce adverse effects.
Further, in vivo toxicity studies with HuArg I [Co]-PEG5000 may
shed further light on the dependence of various normal organs on
circulating plasma arginine.
Previous work with arginine deiminase in hepatocellular carcinoma
patients yielded rare transient, reversible encephalopathy, hyponatremia,
hyperkalemia, anemia, hypoalbuminemia, hyperuricemia, hypofibrino-
genemia, and elevated serum lipase level [2]. Many of these complications
Figure 4. Bonemarrow histopathology. Iliac wings removed, fixed in paraformaldehyde, dehydrated, embedded in paraffin, rehydrated, and
stained with hematoxylin and eosin. Representative photomicroscopic images at 150× magnification. (A) Control PBS. (B) HuArg I [Co]-
PEG5000 5 mg/kg. (C) HuArg I [Co]-PEG5000 10 mg/kg. (D) HuArg I [Co]-PEG5000 10 mg/kg + L-citrulline 100 mg subcutaneously daily.
(E) HuArg I [Co]-PEG5000 10mg/kg+ oral L-citrulline 100mg/ml. Note absence of nuclei and extensive red cell replacement of necrotic bone
marrow in C. Mice in D and E were allowed to recover for 2 weeks before histologic analysis.
Table 1. Serum Arginine Levels after Treatment with Different Doses of HuArg I [Co]-PEG5000
on Days 7 and 28.
Day 7 Day 28
Mean SD Mean SD
Control 60.61 19.01 43.71 14.92
1 mg/kg 32.19* 29.93 53.91 21.84
5 mg/kg 6.63† 2.49 18.09‡ 20.48
10 mg/kg 5.54† 2.01 — —
*P < .05.
†P < .001.
‡P < .01.
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may be been secondary to hepatocellular carcinoma. In a separate study,
arginine deiminase was administered systemically to metastatic melanoma
patients, and no grade 3 or 4 toxicities occurred [8]. Hyperuricemia
and rare, mildly elevated serum lipase and amylase levels were seen
without clinical pancreatitis. Dose was limited by intramuscular injec-
tion volume. Thus, conversion of arginine to citrulline by the arginine
deiminase achieved low serum arginine levels with few—if any—major
adverse effects.
HumanMn2+-containing arginase given to hepatocellular carcinoma
patients generated hyperbilirubinemia, transaminasemia, nausea, diar-
rhea, and abdominal pain [9]. The investigators reported prolonged
serum arginine levels of less than 8 μM. Again, the relationship of
the adverse effect profile to the patient’s disease versus drug was un-
defined. No studies of this agent in other cancer patients have been
reported. Hence, it is difficult to directly compare the safety of arginine
deiminase and Mn2+ arginase. In our studies of the Co2+ arginase both
in tissue culture and in rodents, significant toxicity was seen at high
doses. In our prior tissue culture work, HuArg I [Co]-PEG5000 was
cytotoxic to almost all normal and malignant human cell lines [5]. In a
prior mouse study, 15 mg/kg HuArg I [Co]-PEG5000 given weekly
produced weight loss, hunched posture, lethargy, and bone marrow
necrosis [6]. In our current experiments, we verified the toxicity in mice.
HuArg I [Co]-PEG5000 given at 10 mg/kg twice weekly produced uni-
form lethality, tremendous weight loss, and bone marrow necrosis. The
greater toxicity of the arginase relative to arginine deiminase may be due
to failure of normal tissues to rescue arginine from ornithine—the prod-
uct of arginase. The conversion from ornithine to arginine requires
OTC, which we previously showed was low in many normal primary
cell cultures [5].
The isolated injury to bone marrow and loss of animal weight are
curious toxicities. As noted above, our results substantiate the previ-
ous HuArg I [Co]-PEG5000 mouse study [6]. The lack of changes in
blood cell counts confounds the marrow histology. The poor oral
intake associated with weight loss without changes in serum chemistry
Figure 5. Kaplan-Meier plot of mice survival of HuArg I [Co]-PEG5000 10 mg/kg treated mice with L-citrulline supplementation. Mice
were treated twice weekly for 2 weeks.
Figure 6. Percent mean weight loss from baseline for 10-mg/kg HuArg I [Co]-PEG5000–treated mice at different times of postinitiation
therapy with or without L-citrulline supplementation. Error bars represent SEM. Arrows indicate days of arginase injections. *P < .01.
#P < .001.
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or major organ histology is not explainable by us but may be alleviated
in humans with fluid and/or caloric supplementation. It is also unclear
if arginine deprivation therapy will have as severe an impact on non-
rodents such as primates based on variations in species sensitivity
[10]. Additional studies in nonhuman primates may shed additional
light on the DLT before clinical trials.
Mouse plasma arginine concentrations fell after HuArg I [Co]-
PEG5000 infusion. Plasma arginine remained low for 7 days at
the medium and high dose levels. We were not able to see a signif-
icant difference in circulating arginine concentration to account for
the increased toxicity of the highest dose. A likely explanation is the
modest sensitivity of the high-performance liquid chromatography
assay method with a lower limit of detection close to 4 to 6 μM
and both medium- and high-dose HuArg I [Co]-PEG5000 depleted
arginine at or below this level. In contrast, liquid chromatography–
mass spectrometry provides a lower limit of quantification of 1 μM
and may permit differentiation of posttherapy arginine concentra-
tions [11]. Another reason may be that the higher HuArg I [Co]-
PEG5000 dose impacts more the extracellular tissue concentrations of
arginine, which we have not measured. Nevertheless, HuArg I [Co]-
PEG5000 achieved excellent plasma arginine depletion at a safe dose.
If the HuArg I [Co]-PEG5000 in vivo toxicity is due to the lack of
OTC in normal tissues, supplementation of animals with L-citrulline
may alleviate normal tissue injuries. Our results support this hypoth-
esis. There was dramatic improvement in the 10-mg/kg-dose-level
survival, weight, and marrow histology with i.p. or oral L-citrulline.
L-Citrulline has been safely administered to humans and, in fact, is
associated with improved erection hardness in patients with mild
erectile dysfunction, right ventricular function in patients with heart
failure, reduced arterial stiffness, decreased ECG QT interval, and
absent effects on whole body protein metabolism [12–16]. Our
study suggests that L-citrulline supplementation with HuArg I
[Co]-PEG5000 may improve the therapeutic index—particularly
in patients with ASS-negative metastatic cancers. Confirmation of
the maintenance of in vivo efficacy in a mouse xenograft model
and safety in a nonhuman primate model should be done to extend
these results and facilitate clinical development. Overall, HuArg I
[Co]-PEG5000 is an exciting new therapeutic compound for argi-
nine auxotrophic malignancies.
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